Spyre Therapeutics, Inc. · NASDAQ:SYRE
Henderson Michael Thomas sold 80,000 Spyre Therapeutics, Inc. shares (Form 4)
Traded May 8, 2026 · Filed May 8, 2026
On May 8, 2026, Henderson Michael Thomas (Director) sold 80,000 Spyre Therapeutics, Inc. shares at an average US$74.40 for US$5.95M under a trading plan, leaving 88,606 shares. Filed May 8, 2026 (Form 4).
- Sold
- 80,000 shares
- Price
- US$74.40 average (US$72.57 to US$75.35)
- Value
- US$5.95M
- Holding after
- 88,606 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| May 8, 2026 | Common Stock | Sale | 2,404 | US$72.57 | 166,202 | Direct |
| May 8, 2026 | Common Stock | Sale | 33,513 | US$73.72 | 132,689 | Direct |
| May 8, 2026 | Common Stock | Sale | 24,814 | US$74.76 | 107,875 | Direct |
| May 8, 2026 | Common Stock | Sale | 19,269 | US$75.35 | 88,606 | Direct |
Source
Related
- Spyre Therapeutics, Inc.
- Henderson Michael Thomas
- Spyre Therapeutics, Inc. shareholders
- Form 4 · Henderson Michael Thomas · Jun 23, 2026
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Form 4 · Turtle Cameron · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026